Capital Markets Day: Commercial Execution and Innovation in Obesity Care
9
Commercial execution and innovation
Obesity care
Patient-centric strategy designed to activate more people with
obesity, drive HCP engagement and improve market access
Millon
people >650 million people.
650
live with obesity
50
50
650
0
-10% seek help
~2% are treated
with an AOM
~2.5 million seen by
obesity experts
Treated ~1 million
55
65
with SaxendaⓇ in
2021
Only 25% on treatment
for more than 1 year
13
-2.5———
-1-
0.25
SELECT
semaglutide | effects on cardiovascular
outcomes in people with overweight or obesity
Maximize the value of Novo Nordisk's
superior treatment solutions
Approved products
Saxenda
ONCE-WEEKLY
liraglutide injection
wegovy®
semaglutide injection 2.4 mg
Late-stage pipeline products
Oral semaglutide 50 mg
CagriSema
Ensure obesity is a healthcare priority
needing medical management
Rethink
ObesityⓇ
direct
care
obesity
Truth
About
Weight™
HCP: Healthcare providers; AOM: Anti-obesity medication; CagriSema: Cagrilintide in combination with semaglutide
Novo NordiskⓇ
CMD22
CAPITAL MARKETS DAYView entire presentation